Background
==========

Zygomycosis is a rare life-threatening opportunistic fungal infection in humans, that often complicates diabetes mellitus and primary and acquired immunodeficiencies characterised by defects of the cell-mediated immunity. Other predisposing factors include steroid therapy, organ transplantation and cytotoxic chemotherapy \[[@B1]\]. The causative organism is an aerobic saprophytic fungus belonging to the order of *Mucorales* of the class *Zygomycetes*. It is ubiquitous insoil, grows rapidly and constantly discharges spores into the environment \[[@B2]\]. Infection is usually caused by inhalation of sporangiospores or via direct contamination of skin wounds, especially burns. The lungs, nasal cavity and paranasal sinuses, gut and cutaneous tissues are therefore the most common sites for primary infection. At onset, Rhinocerebral Zygomycosis presents with different clinical features such as blindness, cranial nerve palsies, eye proptosis and pain. Fungal hyphae preferentially invade the walls of blood vessels producing thrombi and infarction. The resulting progressive tissue ischaemia and necrosis of deep tissues may include muscle and fat, ultimately leading to multiorgan failure and sepsis. The central nervous system can be invaded by Zygomycetes either contiguously from adjacent paranasal sinuses (rhinocerebral zygomycosis), or haematogenously from a remote site of infection \[[@B3]\]. We report a case of necrotizing invasive rhinocerebral zygomycosis in a 14-year-old girl with type 1 diabetes and review previous reported cases from 1980 to 2012.

Materials and methods
=====================

Case presentation
-----------------

A 14-year-old caucasian girl is followed at our Department of Pediatrics for type 1 diabetes mellitus since the age of three years with poor glycemic control despite regular insulin therapy. She occurred with a 7-day history of dental pain, facial swelling (extending superiorly from the supraorbital margin and inferiorly to the angle of the mouth), and ecchymosis in the left periorbital region with decreased visual acuity and colour vision, unresponsive to antibiotic therapy with amoxicillin. Physical examination showed left-sided facial numbness, lagophthalmos with inability to complete closure of the left eyelid and tongue deviation to the left. Intraorally there were carious lesions and low sensitivity of the upper teeth. Biochemical investigations revealed neutrophilia and increasing of inflammatory markers. The electromyography showed a severe VII nerve damage. Radiographic examination showed haziness of left maxillary sinus with erosion of lateral sinus wall. Magnetic resonance imaging of her head revealed a marked mucosal thickening of the left maxillary sinus extended to the sphenoid, ethmoid and frontal sinus with moderate inflammatory effusion (Figure [1](#F1){ref-type="fig"}). For three times inflammatory tissue was excised from the sinuses through an Endoscopic Sinus Surgery for microbial eradication and histopathologic examination. The tissue biopsy showed fragments of mucosa lined by respiratory epithelium with chronic aspecific inflammatory infiltrate and growed fungal species belonging to the Zygomycetes. After a 20-day treatment with imipenem, teicoplanin, metronidazole and aciclovir, she was given intravenous amphotericin B to which posaconazole (POS) was immediately replaced, due to the onset of side effects such as hyperglycemia, marked hypothermia and profuse sweating. The follow-up magnetic resonance images showed progression of the disease with significant intracranial extension. The magnetic resonance angiography showed the involvement of the neurovascular retromandibular axis and left cavernous sinus with occlusion of ipsilateral cavernous carotid and increased signal of the walls of the left middle cerebral artery caused by arteritis. She continued antifungal drug therapy and clinic follow-up showing a very slow improvement, a poor glycemic control and many recurrences, leading to blindness of the left eye.

![**Magnetic resonance imaging of head. A.** Postgadolinium T1-weighted axial magnetic resonance image showing nonenhancing tissue (arrow) in the left nasal cavity and periorbital site compatible with necrotic mucosa. **B.** Similar technique showing note semiocclusion of the left internal carotid artery (arrow) and thrombosis of the right cavernous sinus, although there was no radiographic evidence of cerebral infarction.](1824-7288-39-77-1){#F1}

Results
=======

Zygomycosis is rare in pediatric patients, and there are few reports in the literature. We performed a MEDLINE search for articles published in the English-language literature, ages: 0--18 years, from January 1980 to September 2013. The search terms used were: rhinocerebral zygomycosis or mucormycosis and case report.

Our search yielded a total of 25 articles including 28 case reports (Table [1](#T1){ref-type="table"}). Cases included were those with acute zygomycosis infection in the rhinocerebral region diagnosed by histology with or without a positive culture, with hematologic malignancies or type 1 diabetes as predisposing factors. Fifteen out of 28 cases (53.6%) of rhinocerebral zygomycosis from these case series were found in patients with type 1 diabetes, twelve (42.8%) in patients with hematologic malignancies and one (3.6%) in a patient with autoimmune hepatitis.

###### 

Pediatric rhinocerebral zygomycosis: review of the literature from 1980 to 2013

              **Author**               **Cases (Number)**   **Sex**   **Ages (years)**   **Underlying condition**                   **Treatment**                                                                   **Outcome**
  ----------------------------------- -------------------- --------- ------------------ -------------------------- ------------------------------------------------ -----------------------------------------------------------------------------------------------------------
   Kilpatrick et al. \[[@B4]\]. 1984           1               F             18                    DM 1                      Surgery, antifungal therapy                                    Survived with left orbital exenteration and ethmoidectomy.
     Kemper et al. \[[@B5]\]. 1993             1               F             18                    DM 1                          Surgery, L-AmB, HOT                                                   Survived with right eye exenteration
     Garces et al. \[[@B6]\]. 1994             1               M             6            Hematologic malignancy                       Surgery                                                                       Deceased
      Moll et al. \[[@B7]\]. 1994              1            Unknown          12                    DM 1                      Surgery, antifungal therapy                                         Survived with minimal left cranial nerve palsies
      Shah et al. \[[@B8]\]. 1997              1               M             15                    DM 1                             L-AmB and HOT                    Survived with a ventriculoperitoneal shunt, right nonreactive pupil, minimal residual physical disability
      Kameh et al. \[[@B9]\] 1997              1               M         13 months                 DM 1                             Surgery, L-AmB                                                                   Deceased
     Adler et al. \[[@B10]\]. 1998             1               M             16                    DM 1                             Surgery, L-AmB                                                                   Survived
      Lee et al. \[[@B11]\] 1998               1               M             10                    DM 1                             Surgery, L-AmB                                              Survived with open craniotomy for abscess resection
    Khanna et al. \[[@B12]\]. 1998             1               F             11                    DM 1                             Surgery, L-AmB                                                                   Deceased
    Parkin et al. \[[@B13]\]. 2000             2             M; M          13; 3          Hematologic malignancy                     G-CSF, L-AmB                                         Deceased for other cause; survived after bone marrow transplant
     Ryan et al. \[[@B14]\]. 2001              2             F; M           9;3           Hematologic malignancy                    Surgery, L-AmB                                                                   Deceased
   Gessesse et al. \[[@B15]\]. 2001            1               M             11                    DM 1                                Unknown                                                                       Deceased
     Wehl et al. \[[@B16]\]. 2002              1               M          9 months        Hematologic malignancy                        L-AmB                                                                        Deceased
   Hamilton et al. \[[@B17]\]. 2003            1               M             14                    DM 1                       Surgery, antibiotics, HOT                                               Survived with enucleation of right eye
    Simmons et al. \[[@B18]\]. 2005            1               F             8                     DM 1             Surgery, L-AmB, HOT, Interferon-G, POS, GM-CSF                                                   Survived
   Sorensen et al. \[[@B19]\]. 2006            1               F             10           Hematologic malignancy           L-AmB, POS, Caspofungin, surgery                                                  Deceased for other cause
      Popa et al. \[[@B20]\] 2008              1               F             7            Hematologic malignancy                        L-AmB                                          Survived after neurosurgical debridement of the left temporal abscess
    Garner et al. \[[@B21]\]. 2008             2             M; M          5; 15          Hematologic malignancy                      L-AmB, POS                                                                     Survived
     Ganesh et al. \[[@B22]\] 2008             1               M             14                    DM 1                          L-AmB, itraconazole                                                                 Survived
    Tarani et al. \[[@B23]\]. 2009             1               F             12                    DM 1                    L-AmB, GM-CSF, HOT, surgery, POS                                                          Survived
    Ibrahim et al. \[[@B24]\]. 2009            1               F             12                    DM 1                               L-AmB, POS                                                                     Survived
     Skiada et al. \[[@B3]\]. 2009             1               M             2            Hematologic malignancy                     L-Am B, POS                                                                 Vegetative state
    Safder et al. \[[@B25]\]. 2010             1               F             12            Autoimmune hepatitis                     Surgery, L-AmB                                                     Survived with right eye exenteration
    Nirmala et al. \[[@B26]\]. 2011            1               M             12                    DM 1                                 L-AmB                                                                        Survived
    Prasad et al. \[[@B27]\]. 2012             1               F             15           Hematologic malignancy                  Surgery and L-AmB                                                                  Deceased

Abbreviations: *M* Male, *F* Female, *DM 1* Type 1 Diabetes, *L-Amb* Liposomal Amphotericin B, *HOT* Hyperbaric Oxygen Therapy, *POS* Posaconazole, *GM-CFS* Granulocyte Macrophage Colony Stimulating Factor.

In described pediatric cases rhinocerebral zygomycosis presents with a characteristic onset: cranial nerve palsies (66.7% of cases), facial/eye swelling or blindness (40%), eye proptosis (33.3%), periorbital cellulitis or pain (20%), epistaxis, headaches, nasal discharge, decreasing consciousness, dysarthria and otalgia (6.7%).

All cases have the involvement of at least one eye. All patients underwent surgery and/or therapy with amphotericin B and other antifungal agents. The 25% of patients with type 1 diabetes has passed the infection uncomplicated, while the 40% underwent to complications such as eye exenteration, partial loss of vision, invasive surgery and nerve palsies. The overall mortality was 20% in cases with type 1 diabetes and 50% in cases with other predisposing factors. The mortality rate was significantly higher when the central nervous system was involved compared to sinus or sino-orbital involvement only.

Discussion
==========

The Zigomycosis' predisposing factors are uncontrolled diabetes, lymphomas, leukemias, renal failure, organ transplant, long-term corticosteroid and immunosuppressive therapy \[[@B28]\]. Hyperglycemia, usually with an associated metabolic acidosis, is responsible for impaired neutrophil function, neuropathies and vascular insufficiency leading to a diminished resistance to infections and altered tissue response. In ketoacidosis, the acid environment due to the increase in glucose levels and the increase in levels of free iron ions favour fungal growth \[[@B2]\].

The clinical onset of the Rhinocerebral Zygomycosis in our report and in most cases is characterized by cranial nerve palsies, facial/eye swelling and blindness, less frequently by decreasing consciousness.

Mucormycosis is known for having a very poor prognosis: survival rates are currently thought to exceed 80%. Even with successful treatment, Mucorales can reappear during future courses of chemotherapy and neutropenia \[[@B29]\]. There may be predictive factors on the evolution of complications: patients who presented with "blindness" seem to have a higher prevalence of survival (p ≤ 0.04) while patients who presented with "decreased consciousness" seem to have an higher prevalence of death (p ≤ 0.04). With the advent of potent antifungal medications, a combination of surgery, medication and correction of the underlying conditions has provided better outcomes \[[@B26]\]. Surgery needs to be radical with an aim to remove all devitalized tissue, and has to be repeated based on disease progression. The new triazole POS has a broad antifungal spectrum against filamentous fungi. The use of POS seems to be associated with a high prevalence of survival with or without outcome (p ≤ 0.04). This is important as standard therapy with amphotericin B often fails \[[@B23]\].

Conclusion
==========

The zygomycosis may present with specific clinical symptoms in patients with predisposing conditions. "Blindness" seems to be correlated with survival predictive factors while "decreased consciousness" seems to be associated with severe outcome.

Early diagnosis of zygomycosis and meticulous broad spectrum antifungal therapy are necessary to avoid the further spread of infection, which may lead to high morbidity and mortality. The timely use of POS alone or in combination with other therapies seems to be associated with a high prevalence of survival with or without outcome.

Larger studies and populations are needed to test if these relationships are casual or real. It is important to understand and implement the treatment options which can help to manage these patients with peculiar onset before the coltures results. Knowledge of potentially devastating complications can help to prevent the unfortunate consequences.

Written informed consent was obtained from the patient's parents for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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